Evolution of Hypodopaminergic Syndrome in Early Parkinson's Disease

Improvement of Hypodopaminergic Syndrome With Dopaminergic Treatment in Early Parkinson's Disease

The objective of this study is to describe the evolution of hypodopaminergic syndrome in patients with Parkinson's disease.

All patients to be included have been clinically described in the early phase of their disease, before instauration of dopaminergic treatment, in the context of a former study ("Non Motor Aspects in De Novo Parkinson's Disease (Honeymoon) NCT02786667") between june 2012 and june 2016.

3 to 5 years after this study, those patients who started dopaminergic treatment will be evaluated again.

The objective of this study, which takes place 3 to 5 year after the initial evaluation, is to measure the evolution of apathy and other symptoms of the hypodopaminergic syndrome.

Secondary objectives are the evolution of other parameters including pain, personality and behavior. All parameters measured have been determined of each patient in the Honeymoon study.

Inclusion Criteria:

• patients who participated in "Non Motors Aspects in De Novo Parkinson's Disease (Honeymoon)" NCT02786667
• Patients under dopaminergic treatment, with stable dopaminergic treatment for at least 2 months
• Patients with medical insurance
• signed informed consent

Exclusion Criteria:

• diagnosis other than Parkinson's Disease
• dementia (Mattis <130)
• patients protected by law (i.e. pregnant or parturient women)